NCT06081257 is a NA clinical trial of "KB-120" small molecular nutrient and vitamin E in Diminished Ovarian Reserve, sponsored by Women's Hospital School Of Medicine Zhejiang University.

Who is sponsoring NCT06081257?

NCT06081257 is sponsored by Women's Hospital School Of Medicine Zhejiang University.

What drugs are being tested in NCT06081257?

Interventions in NCT06081257: "KB-120" small molecular nutrient and vitamin E, Vitamin E.

What condition does NCT06081257 study?

NCT06081257 studies Diminished Ovarian Reserve.

Is NCT06081257 still recruiting?

NCT06081257 is currently status unknown. Last updated 23 October 2023.

Last reviewed 2023-10-23 · How we verify

NCT06081257

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of "KB-120" Small Molecular Nutrient in Women With Decreased Ovarian Reserve

Status unknown NA Last updated 23 October 2023

What this trial tests

NA trial testing "KB-120" small molecular nutrient and vitamin E in Diminished Ovarian Reserve in 80 participants. Status unknown.

Timeline

15 October 2023

Primary endpoint
5 February 2024

5 July 2024

Quick facts

Lead sponsor	Women's Hospital School Of Medicine Zhejiang University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	15 October 2023
Primary completion	5 February 2024
Estimated completion	5 July 2024

Drugs / interventions tested

"KB-120" small molecular nutrient and vitamin E
Vitamin E (VITAMIN E) — full drug profile →

Conditions studied

Diminished Ovarian Reserve — all drugs for Diminished Ovarian Reserve →

Sponsor

Women's Hospital School Of Medicine Zhejiang University

Who can join

Adults 20 to 40, female only, with Diminished Ovarian Reserve. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

"KB-120" small molecular nutrient is a structural multi-molecular natural nutrient with different components. It is produced from strains and natural plant culture-medium that can be used in food and is designed according to different efficacy of different products by multi-stage solid-liquid complex fermentation technology. The functional directions of the product series involved are: immune function damage repair, intestinal villi damage repair, sperm development machinery damage repair, ovarian function damage repair, liver function damage repair, sleep disorder function damage repair, etc.Previous studies have shown that "KB-120" has good clinical effects on improving the number and function of male germ cells.Luanbao "KB-120" is a compound plant health drink specially for women. This study intends to give "KB-120" small molecule nutrients as nutritional supplement intervention in female patients with ovarian dysfunction, and observe its influence on endocrine function, ovarian reserve function and fertility in patients with ovarian dysfunction.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diminished Ovarian Reserve

Currently open trials in the same condition.

NCT07535983 — Bushen Yiqi Formula Combined With Dehydroepiandrosterone in Women With Diminished Ovarian Reserve · Phase 1, PHASE2 · recruiting
NCT06794047 — The Effect of VitC on IVF Outcome of DOR Patients · NA · recruiting
NCT07124260 — Characterization of Gut and Tongue Coating Microbiota in Patients With Diminished Ovarian Reserve · recruiting
NCT06395623 — Study of Acupoints in Diminished Ovarian Reserve Based on Biological Characteristics · recruiting
NCT06096766 — The Correlation Between Ovarian Function and Serum Biomarkers · recruiting

Other Women's Hospital School Of Medicine Zhejiang University trials

Trials by the same sponsor.

NCT07369986 — Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer · Phase 2 · not yet recruiting
NCT07244965 — Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervica · Phase 2 · not yet recruiting
NCT06561308 — Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer · Phase 2 · recruiting
NCT07106853 — Prenatal Cell-free DNA Screening in Pregnancies With Diverse Genetic Risk Profiles Utilizing Targeted and Whole-exome Se · not yet recruiting
NCT07082530 — A RCT of Labor Induction at 39 Weeks in Low - Risk Women in China · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06081257 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Women's Hospital School Of Medicine Zhejiang University
Last refreshed: 23 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06081257.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing